The reconstitution procedure as published in pharmacy and nursing-education literature. Research-context framing. For educational and research purposes only. Not intended for human use. Not medical advice.
Key points
- 01Volume calculation. Reconstitution volume is calculated before the vial is opened. The identity applied is concentration (mg/mL) equals peptide mass divided by diluent volume, per standard USP compounded-sterile-preparation references.
- 02Workspace preparation. A clean, flat surface is prepared. USP <797> on compounded sterile preparations describes hand hygiene and surface antisepsis with 70% isopropyl alcohol prior to any reconstitution procedure.
- 03Diluent withdrawal. The bacteriostatic water stopper is wiped with a 70% isopropyl alcohol prep pad. The calculated diluent volume is withdrawn into a sterile single-use syringe.
- 04Slow addition to the peptide vial. The diluent is added slowly along the inner wall of the peptide vial. Pharmacy-compounding references describe this angle-of-addition approach to reduce peptide denaturation from mechanical shear.
- 05Gentle swirl, not shaken. Swirl the vial gently until the lyophilized powder is fully dissolved. Peptide-stability references describe the swirl-versus-shake distinction; vigorous agitation is associated with denaturation of labile peptide structures in the published pharmaceutical literature.
- 06Labelling and refrigeration. The vial is labelled with the date of reconstitution and stored at 2–8 °C. Beyond-use dating conventions for reconstituted peptides as reported in pharmaceutical stability literature vary by compound and are the subject of ongoing published research.
Frequently asked questions
What diluent is described for peptide reconstitution?+
Bacteriostatic water for injection, USP (0.9% benzyl alcohol), is described in compounding references for multi-dose reconstitution. Sterile water for injection is described for single-use preparations. The USP monographs define both products.
Why is shaking not described in the literature?+
Mechanical agitation is reported in pharmaceutical stability literature to denature peptide secondary structure and to generate foaming that introduces dosing error. The swirl-until-dissolved convention is described across pharmacy-compounding references and published peptide-handling protocols.
What concentration results from 5 mg of compound in 2 mL of bacteriostatic water?+
The resulting concentration is 2.5 mg/mL, applying the standard dilution identity from USP <797>. This worked example is provided for arithmetic reference only and is not a recommendation.
What is the regulatory status of the compounds frequently discussed in reconstitution literature?+
Compounds such as BPC-157, TB-500, CJC-1295, ipamorelin, and GHK-Cu are not FDA-approved for human use. The FDA's 503A bulk substances review and multiple agency warning letters to compounding pharmacies document the current regulatory posture. Reconstitution procedures are described here for research-context reference only.
How long do reconstituted peptides remain stable, as reported in the literature?+
Beyond-use dating depends on the specific peptide and diluent. Published stability studies report a range of conditions. General pharmaceutical references for bacteriostatically-preserved aqueous preparations describe refrigerated storage timeframes on the order of weeks, subject to compound-specific confirmation.
Should cloudy reconstituted solution be administered?+
No. USP <797> and manufacturer package inserts for FDA-approved injectable products describe visual inspection prior to administration. Persistent cloudiness, precipitation, or visible particulate matter are described as grounds for discard without use.
Is sterile water for injection interchangeable with bacteriostatic water?+
Not for multi-dose preparations. Sterile water for injection contains no preservative and is described for single-use only. Bacteriostatic water contains 0.9% benzyl alcohol as a preservative and supports multi-dose use within its labelled beyond-use period.
Sources
- USP General Chapter <797>. Pharmaceutical Compounding – Sterile Preparations
- USP. Bacteriostatic Water for Injection monograph
- Sikiric P et al.. BPC-157 preclinical review (reconstitution referenced in methods)
- Teichman SL et al., 2006. CJC-1295 clinical pharmacology (methods describe reconstitution)
- FDA. Compounding: Bulk Drug Substances Used in Compounding (503A review)
